Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
DBVT DBV Technologies S.A. daily Stock Chart
DBVT [NASD]
DBV Technologies S.A.
Healthcare | Biotechnology | France
statements
Index- P/E- EPS (ttm)-3.27 Insider Own- Shs Outstand109.80M Perf Week-5.32%
Market Cap410.64M Forward P/E- EPS next Y- Insider Trans- Shs Float21.08M Perf Month-57.55%
Income- PEG- EPS next Q- Inst Own46.27% Short Float15.76% Perf Quarter-67.62%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio5.38 Perf Half Y-57.11%
Book/sh3.98 P/B0.94 EPS next Y- ROA- Target Price19.44 Perf Year-57.31%
Cash/sh- P/C- EPS next 5Y39.74% ROE- 52W Range2.02 - 13.49 Perf YTD-65.05%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-72.28% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low85.15% ATR0.60
Employees315 Current Ratio- Sales Q/Q66.80% Oper. Margin- RSI (14)28.88 Volatility4.86% 12.51%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.30 Prev Close3.91
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume618.13K Price3.74
Recom2.40 SMA20-22.48% SMA50-52.52% SMA200-57.29% Volume185,748 Change-4.35%
Mar-17-20Downgrade Stifel Buy → Hold $18 → $6
Jan-09-20Upgrade Stifel Hold → Buy $10 → $18
Dec-16-19Initiated Citigroup Buy
Sep-05-19Resumed Morgan Stanley Equal-Weight
Jun-17-19Initiated Goldman Buy
Dec-20-18Downgrade Stifel Buy → Hold
Dec-20-18Downgrade Jefferies Buy → Hold
Dec-20-18Downgrade BofA/Merrill Buy → Underperform
Dec-20-18Downgrade Barclays Overweight → Equal Weight
Oct-31-17Upgrade Societe Generale Sell → Hold
Oct-24-17Downgrade Societe Generale Buy → Sell
Oct-23-17Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-23-17Initiated Deutsche Bank Buy $46
Mar-16-17Upgrade Societe Generale Hold → Buy
Sep-26-16Initiated JMP Securities Mkt Outperform
Dec-03-15Initiated Barclays Overweight $58
Oct-23-15Initiated BofA/Merrill Buy
Oct-13-15Initiated Jefferies Buy $47
Sep-15-15Initiated Morgan Stanley Overweight $59
Mar-18-15Initiated H.C. Wainwright Buy $50
Mar-31-20 03:46AM  Analysts Just Made A Major Revision To Their DBV Technologies S.A. (EPA:DBV) Revenue Forecasts Simply Wall St.
Mar-30-20 04:01PM  Ordinary and Extraordinary General Meeting of April 20, 2020 GlobeNewswire
Mar-26-20 11:00AM  Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Mar-20-20 04:15PM  DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F GlobeNewswire +9.73%
Mar-17-20 04:00PM  Monthly information regarding the total number of voting rights and  total number of shares of the Company as of February 29, 2020 and March 4, 2020 GlobeNewswire -55.70%
03:00PM  DBVT Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of DBV Technologies S.A. and Encourages Investors to Contact the Firm ACCESSWIRE
02:51PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT GlobeNewswire
08:48AM  The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment Benzinga
Mar-16-20 04:30PM  DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years GlobeNewswire -10.70%
Mar-09-20 02:58AM  Did You Manage To Avoid DBV Technologies's (EPA:DBV) Devastating 77% Share Price Drop? Simply Wall St. -5.89%
Mar-05-20 11:09AM  3 Top Biotech Stocks With Major Catalysts Approaching TipRanks -8.52%
Mar-04-20 04:30PM  DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update GlobeNewswire
04:01PM  DBV Technologies Announces Closing of Underwriters Option to Purchase Additional Ordinary Shares in the Form of American Depositary Shares in Connection With its Global Offering GlobeNewswire
Mar-02-20 01:30AM  DBV Technologies Announces Partial Exercise of Underwriters Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs) GlobeNewswire
Feb-24-20 04:00PM  DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020 GlobeNewswire
Feb-21-20 09:29AM  DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children GlobeNewswire
Feb-10-20 04:00PM  DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference GlobeNewswire
Feb-06-20 08:00PM  Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020 GlobeNewswire
04:01PM  DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer GlobeNewswire
Feb-04-20 04:30PM  DBV Technologies Announces Closing of Global Offering GlobeNewswire
Feb-01-20 03:53PM  Aimmune's 'First-Of-Its-Kind' Peanut Allergy Drug Receives FDA Approval Benzinga
Jan-30-20 01:30AM  DBV Technologies Announces Pricing of $153.7 million (139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares GlobeNewswire -13.15%
Jan-29-20 04:05PM  DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position GlobeNewswire
Jan-15-20 04:00PM  Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF GlobeNewswire
Jan-14-20 04:00PM  Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Jan-10-20 08:18AM  DBV Technologies is in Overbought Territory: What???s Next? Zacks
Jan-09-20 08:39AM  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results Benzinga +14.77%
Jan-08-20 04:30PM  DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy GlobeNewswire
Jan-02-20 04:30PM  DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer GlobeNewswire
Dec-17-19 04:06PM  Hedge Funds Are Dumping DBV Technologies SA ADR (DBVT) Insider Monkey
Dec-10-19 04:00PM  Monthly information regarding the total number of voting rights and  total number of shares of the Company GlobeNewswire
Nov-19-19 04:00PM  Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Nov-05-19 04:30PM  DBV Technologies to Present at the Stifel 2019 Healthcare Conference GlobeNewswire
Oct-30-19 08:39PM  Heres What Hedge Funds Think About DBV Technologies SA ADR (DBVT) Insider Monkey
Oct-24-19 04:01PM  DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019 GlobeNewswire
Oct-16-19 06:30AM  Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire +5.64%
Oct-15-19 04:30PM  DBV Technologies Announces Closing of Global Offering GlobeNewswire +7.77%
Oct-10-19 01:30AM  DBV Technologies Announces Full Exercise of Underwriters Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs) GlobeNewswire
Oct-09-19 01:30AM  DBV Technologies Announces Pricing of $125 million (114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares GlobeNewswire -7.62%
Oct-08-19 04:18PM  DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position GlobeNewswire -10.58%
Oct-04-19 11:45AM  DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy GlobeNewswire
Oct-02-19 04:00PM  Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Sep-19-19 04:00PM  Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Sep-17-19 06:28AM  Does Market Volatility Impact DBV Technologies S.A.'s (EPA:DBV) Share Price? Simply Wall St.
Sep-16-19 04:19PM  Analyst: DBV's Peanut Allergy Drug Could Outscore Aimmune's On Safety Front Benzinga
Aug-08-19 09:53AM  DBV Resubmits Regulatory Application For Peanut Allergy Drug, Stock Rallies Benzinga +9.52%
Aug-07-19 04:05PM  DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy GlobeNewswire
Aug-01-19 01:30AM  DBV Technologies Reports First Half 2019 Financial Results GlobeNewswire
Jul-19-19 09:06AM  If You Had Bought DBV Technologies (EPA:DBV) Stock Three Years Ago, You'd Be Sitting On A 71% Loss, Today Simply Wall St.
Jul-18-19 01:30AM  Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report GlobeNewswire
Jul-12-19 06:00AM  Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Jul-11-19 06:51PM  Here's Why Aimmune Therapeutics Fell 7% Today Motley Fool
Jun-26-19 01:30AM  DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer GlobeNewswire
Jun-12-19 09:00AM  DBV Technologies S.A. (DBVT) Moves to Buy: Rationale Behind the Upgrade Zacks
Jun-11-19 08:00AM  Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Jun-03-19 01:30AM  DBV Technologies to Attend Upcoming Investor Conferences GlobeNewswire
Jun-01-19 08:00AM  DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019 GlobeNewswire
May-24-19 04:30PM  DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors GlobeNewswire
May-14-19 01:30AM  DBV Technologies Announces Departure of Deputy CEO David Schilansky GlobeNewswire +5.39%
May-11-19 01:27PM  Did Hedge Funds Drop The Ball On DBV Technologies SA ADR (DBVT) ? Insider Monkey
May-06-19 03:30AM  Ordinary and Extraordinary General Meeting of May 24, 2019 - Procedures for Obtaining Preparatory Documents for the General Meeting GlobeNewswire
May-02-19 01:30AM  DBV Technologies to Attend Upcoming Investor Conferences GlobeNewswire
Apr-30-19 01:30AM  DBV Technologies Reports March 31, 2019 Cash Position GlobeNewswire
Apr-11-19 09:17AM  DBV Technologies S.A. (DBVT) Shares March Higher, Can It Continue? Zacks
Apr-08-19 04:30PM  DBV Technologies Announces Closing of Global Offering GlobeNewswire
11:00AM  Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Apr-05-19 01:30AM  DBV Technologies Announces Full Exercise of Underwriters Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (ADS) GlobeNewswire
Apr-04-19 04:36PM  Why DBV Technologies Shares Soared Today Motley Fool +11.73%
02:00AM  DBV Technologies Announces Pricing of $70.4 million (62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares GlobeNewswire
Apr-03-19 04:05PM  DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares GlobeNewswire
Apr-01-19 05:00PM  DBV Technologies Announces Filing of 2018 Document de Référence and 2018 Annual Report on Form 20-F GlobeNewswire
Mar-28-19 04:06PM  Lifshitz & Miller LLP Announces Investigation of Atlas Financial Holdings, Inc., Conduent, Inc., DBV Technologies SA, Ebix, Inc., FTS International, Inc., NV5 Global, Inc., and Venator Materials PLC PR Newswire
Mar-25-19 04:26PM  Peninsula biotech lines up chance to crack the peanut allergy nut American City Business Journals
Mar-19-19 06:39PM  Cohen Milstein Sellers & Toll PLLC Announces Investigation of DBV Technologies S.A. Business Wire
Mar-18-19 03:00PM  FINAL DEADLINE: (DBVT) DBV Technologies S.A. Bronstein, Gewirtz & Grossman, LLC - March 18, 2019 GlobeNewswire
01:46PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DBVT, CVS, CTL and USX GlobeNewswire
01:15PM  FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against DBV Technologies S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:13AM  CLASS ACTION UPDATE for DBVT, UXIN, MHLD and BPI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:19AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against DBV Technologies S.A. (DBVT), Activision Blizzard, Inc. (ATVI) & 22nd Century Group, Inc. (XXII) ACCESSWIRE
Mar-17-19 10:03AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DBVT, AMRN, WTW and CRBP GlobeNewswire
Mar-16-19 06:18PM  EQUITY ALERT: Rosen Law Firm Reminds DBV Technologies S.A. Investors with over $100K in Losses of Important Deadline in Securities Class Action Filed by the Firm DBVT GlobeNewswire
Mar-15-19 08:00PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DBV Technologies, Activision Blizzard, Ferroglobe, and Vale and Encourages Investors to Contact the Firm GlobeNewswire
04:25PM  3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against DBV Technologies S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
03:35PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In DBV Technologies S.A. To Contact The Firm ACCESSWIRE
11:26AM  SHAREHOLDER ALERT: DBVT VALE SVXY CRBP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
10:49AM  DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against DBV Technologies S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Mar-14-19 07:58PM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DBV Technologies S.A. (DBVT) GlobeNewswire
06:34PM  Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against DBV Technologies S.A. (DBVT) GlobeNewswire
03:40PM  FILING DEADLINE-Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DBVT, ASTE and AVEO ACCESSWIRE
03:00PM  (DBVT) DBV Technologies S.A. Bronstein, Gewirtz & Grossman, LLC Class Action Update and Deadline - March 18, 2019 GlobeNewswire
01:00PM  SHAREHOLDER ALERT: DBVT UXIN AVEO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:33AM  (DBVT) DBV Technologies S.A. Bronstein, Gewirtz & Grossman, LLC Class Action Update and Final Deadline - March 18, 2019 ACCESSWIRE
Mar-13-19 10:51AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DBVT, KHC, CTL and INGN GlobeNewswire
10:34AM  (DBVT) DBV Technologies S.A. Bronstein, Gewirtz & Grossman, LLC Class Action Update and Deadline - March 18, 2019 ACCESSWIRE
Mar-12-19 08:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT ACCESSWIRE
03:50PM  DBV MARCH 18 DEADLINE: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against DBV Technologies S.A. DBVT GlobeNewswire
Mar-11-19 11:49AM  CLASS ACTION UPDATE for DBVT, W, ASTE and UXIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:32AM  (DBVT) DBV Technologies S.A. Bronstein, Gewirtz & Grossman, LLC Class Action and Deadline - March 18, 2019 ACCESSWIRE
Mar-10-19 07:05PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sogou, Wayfair, DBV Technologies, and Ferroglobe and Encourages Investors to Contact the Firm GlobeNewswire
10:05AM  CLASS ACTION UPDATE for DBVT, VALE and CAG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestle Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
open in yahoo | open in reuters | open in google